AI-071 is under clinical development by OncoC4 and currently in Phase I for Acute Respiratory Failure. According to GlobalData, Phase I drugs for Acute Respiratory Failure does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AI-071 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AI-071 overview
AI-071 is under development for the treatment of coronavirus disease-2019 pneumonia caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) acute respiratory failure, immune-related adverse events associated with cancer treatment. The drug candidate is administered through intravenous route and acts by targeting SIGLEC.
OncoC4 overview
OncoC4 is a clinical-stage biopharmaceutical company that discovers and develops novel biologicals to treat cancer. The company pipeline products include ONC-782, ONC-783, ONC-784, ONC-841 and A1-071 and A1-061, Its products indications comprise, advance solid tumors, non-small cell lung cancer, solid and hematologic malignancies, immune related adverse events and other oncology. OncoC4’s ONC-392, a next generation anti-CTLA-4 antibody capable of uncoupling cancer therapeutic effect from immunotherapy-related adverse effects. a humanized IgG1 monoclonal antibody enables CTLA-4 to maintain its protective function against autoimmune diseases while enhancing anti-tumor activity. OncoC4 is headquartered in Rockville, Maryland, the US.
For a complete picture of AI-071’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
